Zimmer Biomet Holdings, Inc. sees growth potential with Monogram acquisition enhancing robotics and Paragon 28 integration.

Wall Street expects a year-over-year decline in earnings on higher revenues when Zimmer Biomet (ZBH) reports results for the ...

Zimmer Biomet now expects 5.7-8.2% revenue growth in 2025 with the Paragon 28 acquisition expected to boost growth by around 2.7%, despite the fact the deal only closed in late April.

Zimmer Biomet is down 13.4% since the beginning of the year, and at $90.48 per share, it is trading 25.5% below its 52-week high of $121.44 from May 2024. Investors who bought $1,000 worth of ...

This was the stock's third consecutive day of losses.